Generic maker Teva's profits in proprietary drugs

In an article titled Sector Snap: Generic competition and biotech drugs , one notes the irony that generic maker Teva is facing Hatch-Waxman challenges from Mylan Inc. and Novartis AG over its patented drug Copaxone, a drug for treatment of multiple sclerosis. Teva gets 35 percent of its profit from sales of Copaxone.

Reuters had noted of sales of generics of Teva: Despite two major launches in the last quarter -- generic versions of schizophrenia treatment Zyprexa and cholesterol lowering drug Lipitor with Ranbaxy -- U.S. generic sales fell 5 percent in the quarter to $1.2 billion.